HUTCHMED’s Post

The 65th Annual Meeting of the American Society of Hematology is now on month ago ! Time to acknowledge the very successful presentations of the German Multicenter Study Group for Adult ALL and to thank all contributors: 3 oral presentations and 2 posters. This includes surprising results on potential systemic antileukemic effects of prophylactic CNS irradiation in B-precursor ALL and very promising results of the BOLD trial with dose reduced chemotherapy combined with immunotherapy in older patients with ALL. 1) CNS Irradiation in Adult De Novo B-Precursor ALL / LBL: Results of the Randomized GMALL Trial 08/2013 Indicate Potential Antileukemic Efficacy (Goekbuget et al; Blood 2023, 142 (Supp 1): 828.) 2) Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Patients with Ph/BCR::ABL Negative B-Precursor Adult Lymphoblastic Leukemia (ALL): Preliminary Results of the GMALL Bold Trial  (Goekbuget et al; Blood 2023, 142 (Supp 1): 964) 3) Molecular Subtypes in BCR::ABL1-Positive ALL Are Defined By Cellular Origins and Cooperating Genomic Events (Bastian et al; Blood 2023, 142 (Supp 1): 843. 4) Reshaping MRD Detection Strategies: Next-Generation Sequencing and High DNA Input Identify Previously Missed Measurable Residual Disease in Peripheral Blood of B-Cell Precursor Acute Lymphoblastic Leukemia (Bending et al; Blood 2023, 142 (Supp 1): 4354) 5) Venetoclax and Blinatumomab for Adult Patients with Relapsed/Refractory or MRD Positive Ph- Negative B-Precursor ALL: First Results of the GMALL-Bliven Trial (Fransecky et al; Blood 2023, 142 (Supp 1): 1502) Further Details: https://lnkd.in/ekGa3cQb

Regeneron touts success with bispecific antibody in multiple myeloma trial  Regeneron has released encouraging trial results for its multiple myeloma antibody, #linvoseltamab. The data from the Phase I/II LINKER-MM1 (NCT03761108) study was presented at the European Hematology Association (EHA) Congress 2024 in Madrid, Spain, on 13–16 June.  The 14-month follow up data demonstrated a 71% objective response rate, with 50% of patients achieving a complete response or better and 63% achieving a very good partial response or better, as determined by an independent review committee.  The median overall survival (OS) was 31 months, while the median progression free survival (PFS) and median duration of response (DoR) were not reached, as patients had not progressed yet. The median DoR for all responders was 29 months. https://lnkd.in/gsz5frwg

We are pleased to announce that our new pre-clinical data has been published in the Abstract Book, under the European Hematology Association (EHA)’s official open access journal, HemaSphere Journal. Published under the title “Novel Antigens LMA and KMA Are Expressed on Bone Marrow Plasma Cells from Patients with AL Amyloidosis but They Are Not Detected on Normal Plasma Cells”, the pre-clinical data shows that 100% of amyloidosis patient bone marrow plasma cells express either LMA or KMA. The range of antigen densities was higher for LMA and KMA compared to BCMA. LMA and KMA were detected on CD38-positive cells in all patient samples treated with daratumumab, indicating that HaemaLogiX immunotherapies could be used to treat patients who are not responding to daratumumab. Currently attending the EHA Congress (#EHA2024) in Madrid, Spain, CEO/Managing Director Damian Clarke-Bruce commented: "This research reinforces earlier findings that our novel antigens, KMA and LMA, are predominantly found on malignant plasma cells. This offers a new clinical pathway for addressing AL amyloidosis, multiple myeloma, and some autoimmune diseases.” A sincere thank you to Professor Jesus San Miguel at Clínica Universidad de Navarra and his team in Spain, as well as our research collaborators at The Westmead Institute for Medical Research led by Professor David Gottlieb, for your tremendous research work on this study. For more details on this pre-clinical data and its publication, visit our website via this link: https://bit.ly/4b1QgNg #amyloidosis #novelantigen 

The Hematology Round Up from #ASCO24 (Multiple Myeloma) Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ). https://lnkd.in/d2dRh6Hp Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI). https://lnkd.in/dSjVvk7X Daratumumab (DARA) + bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial. Thank you for your attention and enjoy ASCO Disclosure: This Hematology Round Up was supported by Sanofi https://lnkd.in/d9ic5mpy

#NEWS: IN8bio to present new patient updates from phase 1 trial of INB-100 at American Society of Hematology 2023 Annual Meeting. Learn more: bit.ly/INABprASH23 #AML #leukemia #celltherapy #ASH23 #CancerZero #IN8bio

Vorasidenib has been approved by the FDA for use in the treatment of adults or paediatric patients older than 12 with grade 2 #astrocytoma or #oligodendroglioma who have a susceptible IDH1 or IDH2 mutation. The decision was made based on the results of the #INDIGO trial, which found #vorasidenib to significantly improve progression-free survival in patients. The therapeutic is the first to be approved for this specific subset of patients with astrocytoma or oligodendroglioma. #cancer #clinicaltrials #cancertrials https://lnkd.in/gyTa43qR

Back in December, Dr. Oussama Abla presented his study of: "Langerhans cell histiocytosis: promises and caveats of targeted therapies in high-risk and CNS disease" at the American Society of Hematology Annual Meeting In the video Deanna sat down with him to review the key takeaways from the study, what the challenges are, and how it can take us forward. View the video here: https://lnkd.in/e8JGdGz9

Our congress report from EHA2024 is now available! Follow the link below to download the report from memoinoncology.com #haematology #hematology #EHA2024 #medicaleducation #cancerresearch

I don’t normally do personal posts, given that March is MyelomaAwarenessMonth I thought best to share how the 2nd most common Blood Cancer is not commonly known and can creep up on you. After 9 months of dull upper back pain, 2 different GP visits I was diagnosed at 48 in November 2021 with a t-12 compressed fracture and the cause Myeloma, after initially being told months earlier I had arthritis. It is abnormal, uncontrolled plasma cells that force out your red, white, platelet cells, it causes weakening of the bones, anaemia, kidney problems and an increased risk of infection. In 2022, globally approximately 176,000 cases diagnosed, 35,730 US, 50,000 in Europe, 5800 UK, 4000 Canada, 2625 Australia. Symptoms can be non-specific pain, bruising, back aches, numbness or pins and needles in hands and feet. Learn more and provide support by looking up your local organisations, myeloma.org; myeloma-europe.org; myeloma.ca; lmruk.org; myeloma.org.au . #myelomaresearch #myelomaclinicaltrials #newinmyeloma #myelomaspecialist #hematology #bloodcancer #oncology #advancesinmyeloma #research #cancerresearch #healthtreeresearch #bloodcancer #bloodcancerawareness #cancerawareness #cancercare #cancerfighter #cancerpatients #cancerresearch #clinicalresearch #clinicaltrials #healthtree #hematology #personalizedmedicine #realtech #realworld #realworlddata #realworldevidence #SCT #smolderingmyeloma #stemcells #stemcelltransplant #cartcelltherapy #cartcell

Pegcetacoplan is a novel anti-complement drug used to treat the rare and complement-mediated hematological disease paroxysmal nocturnal hemoglobinuria (PNH). In Annals of Hematology Mendy Boersma-ter Avest presents her findings that personalized dosing has the potential to (cost-neutrally) improve patient friendliness and effectiveness using pharmacokinetically-guided dosing. Read it here: https://lnkd.in/ed9GrY_d